Two-Year Data: Setmelanotide Holds 18.8% BMI Cut in Hypothalamic Obesity
RYTM sits 44% above its 52-week low of $74.5.
Summary
Rhythm's setmelanotide (Imcivree) held an average 18.8% BMI reduction after two years in patients who stayed on the drug continuously, with 16.5% for those who switched from placebo after year one. The data, presented at ObesityWeek 2026, covers 125 patients entering the extension, 81 of whom completed two years. Safety was consistent with earlier acquired hypothalamic obesity trials; 52 of 125 had treatment-related side effects in year two, none serious, and one death was deemed unrelated. This matters because acquired hypothalamic obesity is the label expansion that regulators in Japan and Canada have already cleared, and durable two-year efficacy strengthens the case for US uptake and payer coverage. It also lands with a live takeover situation: AstraZeneca reportedly offered about $10 billion, or $124 a share, and a second unnamed bidder has reportedly countered. Long-term data of this kind supports the higher end of any bid negotiation.
At the time of this announcement, RYTM was trading at $107.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.